PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA

• Vip Viprakasit,
• Yongrong Lai,
• Gian Luca Forni,
• Meng-Yao Lu,
• Liudi Yang,
• Wenhui Shi,
• Loyse Felber Medlin,
• Frederik Lersch,
• Jeevan K. Shetty,
• Luciana Moro Bueno,
• Richard Wei,
• Antonis Kattamis

Affiliations

Vip Viprakasit

1 Siriraj Research Hospital, Mahidol University, Bangkok, Thailand

Yongrong Lai

2 First Affiliated Hospital of Guangxi Medical University, Nanning, China

Gian Luca Forni

3 Ospedale Galliera, Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, Genoa, Italy

Meng-Yao Lu

4 National Taiwan University Hospital, Taipei City, Taiwan

Liudi Yang

5 Bristol Myers Squibb, Shanghai, China

Wenhui Shi

5 Bristol Myers Squibb, Shanghai, China

Loyse Felber Medlin

6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Frederik Lersch

6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Jeevan K. Shetty

6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Luciana Moro Bueno

6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Richard Wei

7 Bristol Myers Squibb, Princeton, NJ, United States

Antonis Kattamis

8 National and Kapodistrian University of Athens, First Department of Pediatrics, Athens, Greece